Efficacy News and Research

RSS

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

Vitamin D and calcium improves bone density in male veterans treated with AEDs

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs (AEDs).

8 Nov 2013

UC researchers receive FDA grant to study generic tacrolimus in high-risk transplant patients

Transplant researchers at the University of Cincinnati have received a grant from the U.S. Food and Drug Administration to study the safety and efficacy of a generic immunosuppressive drug in high-risk transplant patients.

7 Nov 2013

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes and liver disease, as well as Asian people with T2D aged 65 years or older.

7 Nov 2013

Tea helps promote weight loss and improve bone health

Decades worth of research shows that tea-the second most consumed beverage in the world-may help prevent chronic illnesses, including heart disease, certain types of cancer and type 2 diabetes. New research shows tea has been found to help promote weight loss and maintain a healthy weight, improve bone health and activate areas of the brain that bolster attention, problem solving and mood.

7 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.

6 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin, a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis.

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

On behalf of the U.S. Food and Drug Administration, the U.S. Department of Justice today announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce.

5 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Fewer doses of HPV vaccine may confer necessary long-term protection against new infection

NCI scientists report that two doses of a human papillomavirus (HPV) vaccine, trademarked as Cervarix, resulted in similar serum antibody levels against two of the most carcinogenic types of HPV (16 and 18), compared to a standard three dose regimen.

5 Nov 2013

Children's Hospital to participate in drug study to evaluate effects of metformin for treating type 2 diabetes

Children's Hospital Los Angeles will participate in a nationwide drug study evaluating the effects of metformin, a medication that has been shown to be safe and effective for treating type 2 diabetes.

5 Nov 2013

Obese patients who underwent gastric bypass surgery experience weight loss 3 years

For millions of Americans struggling with obesity and considering surgical procedures to achieve weight loss and alleviate obesity-related health complications, a new study adds weight to the health benefits attributed to bariatric surgery.

5 Nov 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease.

4 Nov 2013

Acoustic diode may improve future ultrasound images

Most people know about ultrasound through its role in prenatal imaging: those grainy, grey outlines of junior constructed from reflected sound waves. A new technology called an "acoustic diode," envisioned by researchers in China's Nanjing University, may dramatically improve future ultrasound images by changing the way sound waves are transmitted.

4 Nov 2013

Efficacy News and Research

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

Vitamin D and calcium improves bone density in male veterans treated with AEDs

UC researchers receive FDA grant to study generic tacrolimus in high-risk transplant patients

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Tea helps promote weight loss and improve bone health

Furiex reports financial and operating results for third quarter 2013

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Fewer doses of HPV vaccine may confer necessary long-term protection against new infection

Children's Hospital to participate in drug study to evaluate effects of metformin for treating type 2 diabetes

Obese patients who underwent gastric bypass surgery experience weight loss 3 years

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Acoustic diode may improve future ultrasound images

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News